SCHEMBL127255

SCHEMBL127255

On1[c]cc2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.35
KDM4E B2RXH2 1/20 0.34
NOTUM Q6P988 1/20 0.32
CDK4 P11802 3/20 0.32
CCND1 P24385 3/20 0.32
CYP2A6 P11509 1/20 0.32
ALOX12 P18054 1/20 0.32
POLB P06746 1/20 0.31
MAPK1 P28482 1/20 0.31
ATM Q13315 1/20 0.31
KMT2A Q03164 1/20 0.31
TSHR P16473 1/20 0.31
RAB9A P51151 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MCL1 Q07820 1/20 0.31
CA12 O43570 2/20 0.30
CA9 Q16790 2/20 0.30
BRD4 O60885 1/20 0.30
BRPF1 P55201 1/20 0.30
KAT2B Q92831 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570353 0.71 CDK4 (0.32) CDK4CCND1CYP2A6ALOX12CA12
SCHEMBL137023 0.71 CA12 (0.39) DAOKDM4ENOTUMCDK4CCND1
SCHEMBL3849038 0.71 CA12 (0.34) DAOKDM4ENOTUMCDK4CCND1
SCHEMBL2073401 0.71 CDK4 (0.32) CDK4CCND1CYP2A6ALOX12CA12
SCHEMBL2073630 0.71 CDK4 (0.32) CDK4CCND1CYP2A6ALOX12KMT2A
SCHEMBL650735 0.71 NOS2 (0.34) KDM4ENOTUMCDK4CCND1CYP2A6
SCHEMBL7300677 0.71 CYP2A6 (0.34) CYP2A6CA12CA9BRD4BRPF1
SCHEMBL5327642 0.71 CDK4 (0.33) CDK4CCND1KMT2A
SCHEMBL1642678 0.70 DAO (0.39) DAOKDM4ENOTUMKMT2ATSHR
SCHEMBL5254830 0.69 CDK4 (0.35) KDM4ECDK4CCND1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110713588-B Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2022-08-09 CN claimed
CN-110713588-A Hardmask composition, hardmask layer and method of forming pattern 三星SDI株式会社 2020-01-21 CN claimed
EP-2428577-B1 Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters EASTMAN CHEM CO (US) 2014-01-22 EP claimed
EP-2428577-A1 Preparation of tyrosinase-inhibiting hydroxybenzyl and hydroxypyranonemethyl esters EASTMAN CHEMICAL COMPANY (US) 2012-03-14 EP claimed
US-20110129430-A1 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS EASTMAN CHEMICAL COMPANY (US) 2011-06-02 US claimed
EP-2155886-A2 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS Eastman Chemical Company (US) 2010-02-24 EP claimed
WO-2008153784-A2 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS EASTMAN CHEMICAL COMPANY (US) 2008-12-18 WO claimed
US-20080306144-A1 Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors EASTMAN CHEMICAL COMPANY 2008-12-11 US claimed
WO-2008143777-A1 HYDROQUINONE DERIVATIVE SKIN BRIGHTENING COMPOUNDS EASTMAN CHEMICAL COMPANY (US) 2008-11-27 WO claimed
US-20080286219-A1 Hydroquinone derivative skin brightening compounds EASTMAN CHEMICAL COMPANY 2008-11-20 US claimed
EP-3632910-B1 3,4-DIHYDROQUINOLINONES AS FXR RECEPTOR AGONISTS CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2024-07-17 EP disclosed
WO-2023217232-A1 KINESIN KIF18A INHIBITOR AND USE THEREOF 上海湃隆生物科技有限公司 2023-11-16 WO disclosed
CN-110023334-B anti-GP 73 antibodies and immunoconjugates 科雅博有限责任公司 2023-11-14 CN disclosed
EP-4249479-A1 GLUCOSIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2023-09-27 EP disclosed
EP-3670513-B1 FGFR INHIBITOR AND MEDICAL APPLICATION THEREOF CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN) 2023-09-20 EP disclosed
WO-2000035435-A1 USE OF A MEK INHIBITOR FOR PREVENTING TRANSPLANT REJECTION WARNER-LAMBERT COMPANY (US) 2000-06-22 WO disclosed
EP-0993437-A1 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2000-04-19 EP disclosed
US-6001823-A NOVEL PYRANOSIDES WHICH ARE BELIEVED TO BE CAPABLE OF INTERACTING WITH PERIPLASMIC MOLECULAR CHAPERONES WASHINGTON UNIVERSITY 1999-12-14 US disclosed
WO-1999001421-A1 2-(4-BROMO OR 4-IODO PHENYLAMINO) BENZOIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-01-14 WO disclosed
US-5587112-A DETECTION AND MEASUREMENT OF HIGH ENERGY PARTICLES AND ELECTROMAGNETC RADIATION PHILADELPHIA COLLEGE OF PHARMACY AND SCIENCE (US) 1996-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306144-A1 Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors TYR, TH, HAAO DAO 1049/4885KDM4E 834/4885NOTUM 692/4885
US-20110129430-A1 HYDROXYBENZYL OR HYDROXYPYRANONEMETHYL ESTERS AS TYROSINASE INHIBITORS TYR, TH, HAAO DAO 1049/4885KDM4E 834/4885NOTUM 692/4885
US-20080286219-A1 Hydroquinone derivative skin brightening compounds NQO1, CUTA, TYR DAO 2939/4885KDM4E 3217/4885NOTUM 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.